Dataset Information

Proteomic analysis of gemcitabine-resistant (GemR) versus paired control human pancreatic cancer cells (PCCs)

ABSTRACT: In search of potential markers of treatment response, comparative LC-MS/MS-based proteomic analysis of GemR and paired control PCCs was performed. It includes four different PCC lines including three primary - PCC-1 (c1), PCC-2 (c2), PCC-7 (c3) and Mia PaCa-2 (c4). Cells were maintained in DMEM supplemented with 10% FBS, with or without gemcitabine (50-150 nM) for upto 40 passages. Cell lysates in triplicate from GemR and paired control cells collected at six different passages (p10, p20, p25, p30, p35, and p40) during treatment period were analyzed using LC-MS/MS

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Ingrid Maria Erika Ekman Stensland

LAB HEAD: Tuula A. Nyman

PROVIDER: PXD063320 | Pride | 2025-11-03

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 8

Publications

Proteomic Characterization of Primary Human Pancreatic Cancer Cell Lines Following Long-Term Exposure to Gemcitabine.

Amrutkar Manoj M Li Yuchuan Y Finstadsveen Anette Vefferstad AV Verbeke Caroline S CS Gladhaug Ivar P IP

Proteomes 20251001 4

<h4>Background</h4>Gemcitabine (GEM) remains a cornerstone in the treatment of pancreatic cancer. Upon exposure to GEM, pancreatic cancer cells (PCCs) tend to adapt quickly to outcompete drug-induced cytotoxicity, thereby contributing to treatment failure. Thus, understanding GEM-induced molecular changes in PCCs is important.<h4>Methods</h4>Three primary PCC lines (PCC-1, PCC-2, PCC-7) and Mia PaCa-2 cultured for 40 passages (p) in the absence (control) or presence of GEM (GemR) were assessed f ...[more]

PMID: 41133621

Similar Datasets

Project description:HIGHTLIGHTS-Improved protocol for ISF collection using microdialysis and CSF sampling in mice.-Combined LC‒MS/MS proteomics ISF and CSF analyses for the validation and description of potential new AD biomarkers.-ISF proteomics analysis to track disease progression at the neuronal and glial levels.-Identification of new biomarker candidates for Alzheimer’s disease.ABSTRACTBackground: Mass spectrometry (MS)-based cerebrospinal fluid (CSF) proteomics is an important method for discovering biomarkers of neurodegenerative diseases. CSF serves as a reservoir for interstitial fluid (ISF), and extensive communication between the two fluid compartments helps to remove waste products from the brain.New method: We performed proteomic analyses of both CSF and ISF fluid compartments using intracerebral microdialysis to validate and detect novel biomarkers of Alzheimer's disease (AD) in APPtg and C57Bl/6J control mice.Results: We identified up to 625 proteins in ISF and 4,483 proteins in CSF samples. By comparing the biofluid profiles of APPtg and C57Bl/6J mice, we detected 37 and 108 significantly up- and downregulated candidates, respectively. In ISF, 7 highly regulated proteins, such as Gfap, Aldh1l1, Gstm1, and Txn, have already been implicated in AD progression, whereas in CSF, 9 out of 14 highly regulated proteins, such as Apba2, Syt12, Pgs1 and Vsnl1, have also been validated to be involved in AD pathogenesis. In addition, we also detected new interesting regulated proteins related to the control of synapses and neurotransmission (Kcna2, Cacng3, and Clcn6) whose roles as AD biomarkers should be further investigated.Comparison with existing methods: This newly established combined protocol provides better insight into the mutual communication between ISF and CSF as an analysis of tissue or CSF compartments alone.Conclusions: The use of multiple fluid compartments, ISF and CSF, for the detection of their biological communication enables better detection of new promising AD biomarkers.KEYWORDSAlzheimer’s disease, CSF, ISF, proteomics, biomarkers, microdialysis, mass spectrometry, protein identification, neurodegeneration, brain fluids, expression profilesDATA AVAILABILITYDOI: 10.17605/OSF.IO/VWQ58PUBLICATIONS using this dataset:1)Gorska et al. 2024, Journal of Neuroscience Methodshttps://doi.org/10.1016/j.jneumeth.2024.1102392) to come

			Action	DRS
	LC-MS-files_C3.zip	Other
	LC-MS-files_C4.zip	Other
	LC-MS_files_C1.zip	Other
	LC-MS_files_C2.zip	Other
	reportC1.zip	Other